Arcellx (ACLX) Stock Overview
Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ACLX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Arcellx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$88.85 |
| 52 Week High | US$107.37 |
| 52 Week Low | US$47.86 |
| Beta | 0.31 |
| 1 Month Change | 14.87% |
| 3 Month Change | 31.45% |
| 1 Year Change | -6.74% |
| 3 Year Change | 362.04% |
| 5 Year Change | n/a |
| Change since IPO | 428.87% |
Recent News & Updates
Analysts Have Lowered Expectations For Arcellx, Inc. (NASDAQ:ACLX) After Its Latest Results
Aug 10
Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market
Jul 15Recent updates
Analysts Have Lowered Expectations For Arcellx, Inc. (NASDAQ:ACLX) After Its Latest Results
Aug 10Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market
Jul 15We're Not Very Worried About Arcellx's (NASDAQ:ACLX) Cash Burn Rate
Jul 11We Think Arcellx (NASDAQ:ACLX) Can Easily Afford To Drive Business Growth
Apr 09Arcellx Impressive Safety Data Leaves Doubts
Mar 17Need To Know: Analysts Just Made A Substantial Cut To Their Arcellx, Inc. (NASDAQ:ACLX) Estimates
Mar 05Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy
Jan 16Risks To Shareholder Returns Are Elevated At These Prices For Arcellx, Inc. (NASDAQ:ACLX)
Dec 20A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)
Oct 28Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma
Sep 10Arcellx: Navigating The CAR T-Cell Revolution
Jan 30Shareholder Returns
| ACLX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.5% | 0.4% | -1.5% |
| 1Y | -6.7% | -0.7% | 14.4% |
Return vs Industry: ACLX underperformed the US Biotechs industry which returned -0.6% over the past year.
Return vs Market: ACLX underperformed the US Market which returned 15.1% over the past year.
Price Volatility
| ACLX volatility | |
|---|---|
| ACLX Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ACLX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACLX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 163 | Rami Elghandour | www.arcellx.com |
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Arcellx, Inc. Fundamentals Summary
| ACLX fundamental statistics | |
|---|---|
| Market cap | US$5.12b |
| Earnings (TTM) | -US$187.99m |
| Revenue (TTM) | US$56.98m |
Is ACLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACLX income statement (TTM) | |
|---|---|
| Revenue | US$56.98m |
| Cost of Revenue | US$172.25m |
| Gross Profit | -US$115.27m |
| Other Expenses | US$72.72m |
| Earnings | -US$187.99m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.39 |
| Gross Margin | -202.30% |
| Net Profit Margin | -329.93% |
| Debt/Equity Ratio | 0% |
How did ACLX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/16 18:04 |
| End of Day Share Price | 2025/10/16 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arcellx, Inc. is covered by 26 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Carter Gould | Barclays |
| Peter Lawson | Barclays |